Clinical and Molecular Analysis of Patients with Hypophosphatemic Rickets: Genetic Variant Spectrum
Journal of the Endocrine Society · 2026-11-11
DOI: 10.1210/jendso/bvag258 ↗Abstract
Abstract Background X-linked hypophosphatemia (XLH) is the most common hereditary form of hypophosphatemic rickets, caused by loss-of-function variants in PHEX. Genetic confirmation is increasingly important for treatment eligibility, particularly for burosumab. Limited data exist on genetic testing outcomes in Latin American populations. Objectives To characterize the genetic variant spectrum, determine the diagnostic yield of comprehensive panel testing, and describe ACMG-based variant classification in patients with clinically suspected hypophosphatemic rickets. Methods Retrospective cohort of 152 patients tested during 2019-2026 at Shriners Hospitals for Children, Mexico City. Comprehensive gene panels were performed at two reference laboratories: Invitae (13-17 genes, depending on panel version) and Mendelics (17 genes, including ALPL). Variants were classified according to ACMG guidelines. Results Of 152 patients, 112 (73.7%) had a molecular diagnosis based on pathogenic or likely pathogenic (P/LP) variants. Eighty-two unique P/LP variants were identified (12 recurrent, 70 rare). PHEX accounted for 96.4% of diagnosed cases, confirming XLH as the primary diagnosis. Variant types included frameshift (30.5%), nonsense (18.3%), splice site (18.3%), copy number variants (18.3%), and missense (14.6%); truncating variants represented 84.1% of unique variants. The most common recurrent variant was PHEX c.1735G>A (p.Gly579Arg), found in 10 unrelated patients. Conclusions Comprehensive genetic panel testing demonstrated a high diagnostic yield (73.7%) in patients with suspected hypophosphatemic rickets. PHEX variants predominated, confirming XLH as the primary etiology. These findings support the clinical utility of genetic testing for diagnostic confirmation and treatment eligibility.
EUVIMED